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The findings of clinical and in vitro research support the theory that infective endocarditis (IE)-causing
bacteria form biofilms and that biofilms negatively affect treatment outcomes. The purpose of the present study
was to quantify the biofilm formation of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA)
isolates obtained from patients with IE and to evaluate the in vitro activities of daptomycin and vancomycin
alone and in combination with rifampin (rifampicin) or gentamicin while monitoring the isolates for the
development of resistance. A high-inoculum, stationary-phase infection model of IE was used to simulate the
pharmacokinetics in humans of daptomycin at 6 mg/kg of body weight/day, vancomycin at 1.25 g every 12 h
(q12h) alone and in combination with rifampin at 300 mg every 8 h, and gentamicin at 1.3 mg/kg q12h. Two
randomly selected clinical MRSA isolates were obtained from patients with IE; both MRSA isolates quanti-
tatively produced biofilms. The time to bactericidal activity in the presence of daptomycin was isolate depen-
dent but was achieved by 24 h for both MRSA isolates. Vancomycin did not achieve bactericidal activity
throughout the experiment. At 24, 48, and 72 h, daptomycin-containing regimens had significantly more
activity (greater declines in the mean number of CFU/g) than any of the vancomycin-containing regimens (P
0.03). Rifampin and gentamicin antagonized or delayed the bactericidal activity of daptomycin (against MRSA
B346846 for rifampin and against both isolates for gentamicin) in the first 24 h. Increases in the daptomycin
and vancomycin MICs were not observed. We conclude that in an IE model of biofilm-forming MRSA,
daptomycin monotherapy has better in vitro activity than daptomycin in combination with rifampin or
gentamicin or any vancomycin-containing regimen studied within the first 24 h. Further investigations are
needed to understand the initial delay in bactericidal activity observed when gentamicin or rifampin is
combined with daptomycin.
Biofilm-forming Staphylococcus aureus isolates are fre-
quently found on prosthetic devices and in deep tissue infec-
tions (21, 43), and both prosthetic devices and deep tissue
infections serve as common sources for bacteremia. Clinical
research supports the theory that infective endocarditis (IE)-
causing bacteria form biofilms (14, 19) and that S. aureus
isolates recovered from the blood of patients with IE tend to
produce biofilms at a high inoculum and during the stationary
phase of growth (24, 43). These isolates also typically carry
accessory gene regulator (agr) groups I and II, which regulate
the production of autolysins that promote biofilm formation
(21, 43, 44). Despite this information, there are limited data
about the biofilm-forming capabilities of S. aureus isolates that
cause IE (SAIE).
Until recently, effective antimicrobial therapy for methicillin
(meticillin)-resistant S. aureus (MRSA) bacteremia and IE was
limited to vancomycin. Although vancomycin has commonly
been used since the 1980s for the treatment of MRSA infec-
tions, including endocarditis, several published studies indicate
that it has limited efficacy because of bacterial resistance, bac-
terial tolerance, and poor tissue penetration (8, 22, 36). Pa-
tients with SAIE treated with vancomycin alone may still be
bacteremic (as indicated by positive blood cultures) after 7 to
10 days of therapy (25, 26). Guidelines for the treatment of
SAIE recommend the use of combination therapy with vanco-
mycin plus gentamicin or rifampin (rifampicin) (2, 3, 41). How-
ever, these combinations can be problematic because gentami-
cin increases the risk of nephrotoxicity and rifampin increases
the potential for drug interactions via its induction of cyto-
chrome P450 metabolism. In addition, this recommendation is
based on limited clinical data.
Daptomycin, a novel lipopetide antimicrobial agent, received
FDA approval in May 2006 for the treatment of bacteremia
and right-sided SAIE caused by methicillin-susceptible and
-resistant strains (12). The FDA indication is for monotherapy
against gram-positive pathogens; however, the guidelines rec-
ommend combination therapy for SAIE. Data to support the
optimal dose of daptomycin required for it to have activity
when it is combined with commonly used synergistic agents
such as gentamicin and rifampin are lacking. In addition, lim-
ited information about the activity of daptomycin in the pres-
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ence of biofilm-forming S. aureus has been published (23, 32,
35, 37).
The purpose of this study was to quantify the biofilm for-
mation of S. aureus isolates obtained from patients with SAIE,
to assess the in vitro activities of daptomycin and vancomycin
alone and in combination with rifampin or gentamicin, and to
evaluate the development of resistance in a high-inoculum,
stationary-phase bacterial (biofilm) model of IE.
(This work has been presented in part at the 108th General
Meeting of the American Society for Microbiology, Boston,
MA, 1 to 5 June 2008 [abstr. A-076].)
MATERIALS AND METHODS
Bacterial strains. Clinical MRSA isolates B346846 and B341002 were ob-
tained from the Cubicin bacteremia and IE registration trial (ClinicalTrials.gov
number NCT00093067) and were supplied by Cubist Pharmaceuticals, Inc. (Lex-
ington, MA) (17). Both isolates are mecA positive and were baseline bloodstream
isolates from patients with documented IE. Previous testing identified isolate
B346846 as having the genetic variants agr type I, spa type 17, and staphylococcal
chromosomal cassette mec (SCCmec) type IV and isolate B341002 as carrying agr
type II, spa type 2, and SCCmec type II.
Antimicrobial agents. Vancomycin (lot no. 087K0694), rifampin (lot no.
087K187), and gentamicin (lot no. 016K1120) were purchased from Sigma Chemical
Company, St. Louis, MO. Daptomycin (lot no. CDCX01) was obtained from Cubist
Pharmaceuticals, Inc. Stock solutions of each antibiotic were freshly prepared at the
beginning of each week and were kept frozen at 80°C.
Medium. Mueller-Hinton broth (Becton Dickinson and Co., Sparks, MD)
supplemented with calcium and adjusted to physiologic conditions of 50 mg/liter
calcium chloride (ionized Ca; 1.03 to 1.23 mmol/liter) and 12.5 mg/liter magne-
sium was used for all in vitro pharmacodynamic models. Bacto tryptic soy broth
(Becton Dickinson and Co.) supplemented with 1% glucose and 50 mg/liter
calcium chloride was used to optimize biofilm production in the minimal biofilm
eradication concentration (MBEC) assay (38). Calcium quantification was veri-
fied in all test broths by the Providence Veterans Affairs Medical Center (Prov-
idence, RI) in-house clinical laboratory with an Abbott (Abbott Park, IL) Ar-
chitect c8000 apparatus. Colony counts were determined by using tryptic soy agar
(TSA; Difco, Becton Dickinson).
Susceptibility. The MICs of the study antimicrobial agents were determined by
the Etest methodology and broth microdilution according to the guidelines of the
Clinical and Laboratory Standards Institute (10, 11). The MICs were also de-
termined at a high inoculum (109 CFU/g), as described previously (24), and in
the presence of 4 g/dl of human albumin (Rhode Island Blood Bank, Provi-
dence), which contained free fatty acids to more closely mimic normal human
protein binding (William Craig, University of Wisconsin—Madison, personal
communications). The minimum bactericidal concentrations were determined by
inspection of the colony counts on wells displaying no visible growth (40). All
samples were incubated at 37°C in ambient air for 24 h. Antimicrobial suscep-
tibility was also evaluated in the presence of established 24-h biofilms by using a
Calgary biofilm MBEC pin-lid device (9). The MBEC was defined as the minimal
concentration of an antibiotic required to eradicate the growth in the biofilm.
In vitro pharmacodynamic infection model with SEVs. A previously described
simulated endocardial vegetation (SEV) model was used to evaluate several
antibiotic regimens. S. aureus was used at a high inoculum to represent the
organism density often associated with sequestered infections such as endocar-
ditis (20, 24). A bacterial inoculum of approximately 109 CFU/g was achieved in
the SEVs by combining 50 l of a high-inoculum organism suspension, 500 l of
human cryoprecipitate antihemolytic factor from human volunteer donors
(Rhode Island Blood Bank), and 5 l of a platelet-saline suspension (250,000 to
500,000 platelets per clot) in siliconized Eppendorf tubes. After vortex mixing to
ensure a homogeneous mixture, a monofilament line and then 50 l bovine
thrombin (5,000 U/ml) were added to each Eppendorf tube. SEVs were then
removed from the tubes and inserted into the model. This methodology results
in SEVs containing approximately 3 to 3.5 g/dl of albumin and 6.8 to 7.4 g/dl of
total protein (20, 28). Recent studies have confirmed that the addition of albu-
min does not significantly affect the activity of time-kill studies; therefore, addi-
tional albumin was not added to the supplemented broth (7, 39).
An in vitro pharmacodynamic model consisting of a 250-ml one-compartment
glass apparatus with ports in which the SEVs were suspended was utilized for all
simulations (28). The apparatus was prefilled with medium and antibiotics, and
over a 72-h period, the medium and antibiotics were administered as boluses into
the central compartment via an injection port. The models were placed in a 37°C
water bath throughout the procedure with a magnetic stir bar for thorough
mixing of the drug in the model. Fresh media were continuously supplied and
removed from the model via a peristaltic pump set (Masterflex; Cole-Parmer
Instrument Company, Chicago, IL) to simulate the half-lives of the antibiotics.
Daptomycin was administered to simulate a dose of 6 mg/kg of body weight
every 24 h (maximum concentration of drug in plasma [Cmax], 98.6 g/ml;
half-life, 8 h; area under the concentration-time curve from time zero to 24 h
[AUC0–24], 747 g  h/ml) (12). Vancomycin was administered to simulate a dose
of 1.25 g every 12 h (Cmax, 45 g/ml; minimum concentration of drug in plasma
[Cmin], 15 to 20 g/ml; half-life, 6 h; AUC0–24, 300 g  h/ml) (27). Gentamicin
was administered to simulate a dose of 1.3 mg/kg every 12 h (Cmax, 6 g/ml; Cmin,
0.4 g/ml; half-life, 2 h) Rifampin was administered to simulate an intravenous
dose of 300 mg every 8 h (Cmax, 10.5 g/ml; half-life, 4 h; AUC0–24, 85.7
g  h/ml) (30). For the experiments with the combination regimen, the elimi-
nation rate was determined for the drug with the shortest half-life; supplemental
drug was added for the agent with the longer half-life (5). Experiments with all
models were performed in triplicate to ensure reproducibility. In addition, sim-
ulations were performed in the absence of antibiotics to ensure the adequate
growth of the organisms in the model.
Two SEVs were removed from each model, for a total of six SEVs each at
times of 0, 4, 8, 24, 32, 48, and 72 h. Once the SEVs were removed, they were
immediately homogenized, diluted, and plated onto TSA; samples were then
incubated at 37°C for 24 h, and the colony count was enumerated. Antimicrobial
carryover was minimized by serial dilution (10 to 10,000) of plated samples in
conjunction with vacuum filtration, as described previously (24). Colonies were
counted on filter paper containing a grid with a limit of detection of 102 CFU/g.
Activity defined. The reductions in the log10 number of CFU/g over 72 h were
determined by plotting time-kill curves. Bactericidal activity (99.9% killing) was
defined as a 3-log10-CFU/g change and bacteriostatic activity was defined as a
3-log10-CFU/g change in the colony count from that for the initial inoculum at
24, 48, and 72 h. The time required to kill 99.9% of the bacteria present was
determined by nonlinear regression (by use of a minimum of four data points) if
r2 was 0.95 or by visual inspection.
In addition, reductions in the colony counts were determined over a 72-h
period and were compared between regimens. Synergy was defined as a2-log10
decrease in the number of CFU/g between the combination regimen and its most
active constituent after 24 h and when the number of surviving organisms in the
presence of the combination was 2 log10 CFU/g below the starting inoculum
(1). Indifference was defined as a 2-log10-CFU/g increase in killing in compar-
ison to that achieved with the most active single agent. Combinations that
resulted in bacterial growth of 2 log10 CFU/g in comparison to that achieved
with the most active single agent were considered antagonistic (1).
Pharmacodynamic analysis. Cmax-to-MIC ratios, the percentage of time that
the concentration remained above the MIC, and AUC0–24-to-MIC ratios were
calculated for each antibiotic and were compared to the values provided in the
literature. The MICs used in these analyses were obtained from broth microdi-
lution results, since that was the methodology used to obtain the values reported
in the literature.
Pharmacokinetic analysis. Samples for pharmacokinetic analysis were ob-
tained through the injection port at 0.5, 1, 2, 4, 8, 24, 32, 48, 56, and 72 h for
verification of the target antibiotic concentrations. All samples were stored at
80°C until they were ready for analysis. Daptomycin concentrations were de-
termined by a previously described and validated high-pressure liquid chroma-
tography (HPLC) method (Center for Anti-Infective Research and Develop-
ment, Hartford, CT) (13). Gentamicin and vancomycin concentrations were
determined by a homogeneous particle-enhanced turbidmetric immunoassay
(Architect, Multigent; Abbott Diagnostics, Abbott Park, IL) at the Providence
Veteran Affairs Medical Center. The gentamicin assay has a range of detection
of 0.3 to 10.0 g/ml and a between-day sample precision and a coefficient of
variation of 1.35% and 2.75%, respectively. The vancomycin assay has a de-
tection range of 0.5 to 80.0 g/ml and a between-day sample precision and
coefficient of variation of 1.6% and 5.0%, respectively. Rifampin concentra-
tions were evaluated by HPLC (National Jewish Medical and Research Center,
Denver, CO), as described previously (30). The half-life, AUC, Cmax, and Cmin
of the antibiotics were determined by the trapezoidal method with PK Analyst
software (version 1.10; MicroMath Scientific Software, Salt Lake City, UT).
Resistance and MIC increases. Changes in the MICs were evaluated for the
monotherapy and the combination therapy models at 24, 48, and 72 h. To assess
the development of resistance, 100-l samples were collected at these time points
and were plated on TSA plates containing two-, four-, and eightfold the MIC of
the respective antibiotic. In addition, MIC testing was conducted for rifampin,
daptomycin, vancomycin, and gentamicin by Etest. Samples were evaluated di-
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rectly from the model to prevent the passing of bacteria on antibiotic-containing
plates and to optimize the detection of MIC changes. The plates were examined
for growth after 24 and 48 h of incubation at 37°C.
Statistical analysis. Changes in bacterial growth (CFU/g) at 4, 8, 24, 48, and
72 h and the time to 99.9% killing were compared by two-way analysis of variance
with Tukey’s post-hoc test. A P value of 0.05 was considered significant. All
statistical analyses were performed with SPSS statistical software (release 15;
SPSS, Inc., Chicago, IL).
RESULTS
Susceptibility testing. Daptomycin, vancomycin, gentamicin,
and rifampin were active against both of the biofilm-forming
MRSA clinical isolates evaluated in this study (Table 1). In the
presence of human albumin (4 g/dl), the MICs for daptomycin
and vancomycin increased eight- and twofold, respectively. In
the presence of high inocula, there were also increases in the
daptomycin and vancomycin MICs of 16- and 4-fold, respec-
tively. These results are consistent with those presented in
other reports (24) and may be explained by the relatively high
and moderate levels of protein binding exhibited by daptomy-
cin (93%) and vancomycin (55%), respectively (15, 27). There
was a minimal increase in the gentamicin and rifampin MICs
(less than or equal to twofold each) when the MRSA isolates
were evaluated in the presence of albumin and/or at high
inocula. This is also consistent with the findings presented in
previously published studies (24).
In vitro pharmacokinetics and pharmacodynamics. The
pharmacokinetic parameters of the antimicrobial agents were
within the targeted range and can be found in Table 2. All
Cmaxs obtained were within 10% of the targeted Cmax, and the
vancomycin AUC/MIC ratios ranged from 641 to 1,282 for
each clinical isolate.
Biofilm production quantified. Both clinical MRSA isolates
exhibited biofilm formation. The biofilm-forming S. aureus
control strain (strain ATCC 35556) demonstrated biofilm for-
mation with an optical density at 570 nm (OD570) of 0.68 
0.08. The clinical isolates had consistent biofilm production
(OD570, 0.65  0.09), and the non-biofilm-forming control
isolate did not produce a biofilm (OD570, 0.36  0.04).
Antimicrobial activity in a formed biofilm assay. The dap-
tomycin and vancomycin MBECs were 8 to 16 and 64 to 128
g/ml, respectively, for the clinical isolates. The gentamicin
and rifampin MBECs were 256 to 512 g/ml and 0.0625 g/ml,
respectively, for the biofilm-forming clinical isolates, thus in-
dicating that rifampin demonstrates activity in a preformed
biofilm assay.
The antimicrobial activities of daptomycin and vancomycin
were evaluated alone and in combination with gentamicin or
rifampin against a high inoculum (109 CFU/g) of biofilm-form-
ing MRSA isolates in a simulated IE vegetation model (Table
3; Fig. 1). Daptomycin monotherapy achieved bactericidal ac-
tivity against strain B341002 at 8 h and against strain B346846
at 24 h. At 24 h, daptomycin monotherapy demonstrated sig-
nificantly better activity than daptomycin in combination with
rifampin or gentamicin against MRSA B346846 (mean differ-
ences, 2.18 [P  0.03] and 4.61 [P  0.001], respectively) and
daptomycin plus gentamicin against MRSA B341002 (mean
difference, 2.70 [P 0.002]). The mean differences at 24 h also
met the criteria for antagonism; rifampin antagonized dapto-
TABLE 1. MIC results obtained with standard and high inocula for clinical isolates and MBEC results for all isolates
Antimicrobiala
MIC (g/ml)b MBEC (mg/liter)c
MRSA B341002 MRSA B346846
MRSA B341002 MRSA B346846Standard
inoculum
High
inoculum
Standard
inoculum
High
inoculum
Daptomycin 0.5 8 0.5 8 16 8
Daptomycin with albumin 4 8 4 8 NAd NA
Vancomycin 0.5 2 1 4 128 64
Vancomycin with albumin 1 4 1 4 NA NA
Gentamicin 0.5 0.5 0.25 0.5 256 256
Gentamicin with albumin 0.5 0.25 0.125 0.25 NA NA
Rifampin 0.02 0.25 0.06 0.5 0.0625 0.0625
Rifampin with albumin 0.06 0.06 0.06 0.06 NA NA
a For antimicrobials with albumin, albumin was added to the broth at 4 g/dl.
b The standard inoculum was 5  105 CFU/ml, and the high inoculum was 5  109 CFU/ml.
c A Calgary biofilm device was used to determine the antimicrobial activity in a formed biofilm. The values were obtained by determination of the plate counts, and
the limit of detection was 2.4 CFU/ml.
d NA, not applicable.
TABLE 2. Targeted values and values of pharmacokinetic parameters obtained with SEV infection model
Regimena
Cmax (g/ml) Half-life (h) AUC0–24 (g h/ml)
Targeted Obtainedb Targeted Obtained Targeted Obtained
Daptomycin, 6 mg/kg every 24 h 98.6 88.57 0.35 8 7.16  0.59 747 825
Vancomycin, 15 mg/kg every 12 h 45 42.32 11.9 6 6.04  0.17 300 341
Gentamicin, 1.3 mg/kg every 12 h 6 5.70 0.98 2 2.91  0.87
Rifampin, 300 mg every 8 h 10.5 9.67  0.27 4 5.24  0.29 86 133
a The regimens are based on those for a 75-kg patient.
b The values obtained are means  standard deviations.
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mycin’s activity against MRSA B346846, and gentamicin an-
tagonized daptomycin’s activity against both isolates. There
were no significant differences in activity between daptomycin
alone and daptomycin plus rifampin or gentamicin at 48 or
72 h, nor was synergy or antagonism noted by 48 or 72 h.
Vancomycin monotherapy did not achieve bactericidal ac-
tivity against either clinical isolate tested at any time point.
There was also no significant difference between vancomycin
monotherapy and the regimens of vancomycin plus rifampin or
vancomycin plus gentamicin at any time point during the 72-h
experiment. At 24, 48, and 72 h, the daptomycin-containing
regimens had significantly (P  0.05) more activity (as mea-
sured by a decline in the mean numbers of CFU/g) than any of
the vancomycin-containing regimens (Table 3). Gentamicin
and rifampin monotherapies did not demonstrate any signifi-
cant activity during the study. Resistance (defined as an MIC
of 32 g/ml) occurred in the rifampin monotherapy models
by 24 h, and the gentamicin MICs increased fourfold within
24 h. The vancomycin and daptomycin MICs varied at each
time point but never exceeded 2 g/ml.
DISCUSSION
Left-sided IE is a sequestered infection that often yields a
high bacterial density (108 to 1010 organisms per gram of tis-
sue) (4). IE can develop when an organism attaches to the
heart valve and forms a vegetation. The limited blood supply to
this area and the high bacterial load result in a blunted im-
mune response and limited antimicrobial drug access. As the
infection progresses, the rates of bacterial metabolism and cell
division are reduced and biofilms may develop as a result of
nutrient limitation and autolysin production. Clinical cure can
be achieved, but the prolonged administration of bactericidal
cell-wall-active antibacterial agents is required to sterilize the
vegetation. Treatment success depends on multiple factors,
including patient comorbidities, the location of the vegetation
(right-sided versus left-sided endocarditis), and surgical inter-
vention (17, 18). Limited antibiotic penetration into the vege-
tation partially explains why left-sided IE is considered a dis-
ease which must be treated surgically. The exact cause of most
treatment failures is unknown; however, it is likely related to
the ability of the bacteria to form biofilms (14, 19). The bac-
teria embedded in a biofilm are less susceptible to antibiotics
by virtue of their reduced growth rates, nutrient limitation, and
adaptive stress responses (6, 42).
We report here the findings of studies of daptomycin and
vancomycin monotherapies and combination therapy with ri-
fampin or gentamicin in an in vitro model of endocarditis
caused by biofilm-forming clinical isolates. The addition of
gentamicin or rifampin did not significantly improve the activ-
ity of daptomycin or vancomycin (Fig. 1). Daptomycin had
significantly better activity than vancomycin against both of the
biofilm-forming MRSA isolates, and no MIC shifts were ob-
served. Of interest, during the first 24 h, rifampin antagonized
and delayed the bactericidal activity of daptomycin against
MRSA B346846, and gentamicin antagonized and delayed the
bactericidal activity of daptomycin against both isolates. Although
contradictory results can often be found in the literature (31),
antagonistic activity is often observed when rifampin is added to
bactericidal agents in high-inoculum infections and against bio-
film-forming S. aureus (29, 31, 34). In addition, the inhibition of
bacterial RNA synthesis may be responsible for delaying the kill-
ing activities of cell-wall-active agents. Clinical studies have rarely
demonstrated bactericidal activity with rifampin combination
therapy for the treatment of SAIE (25, 31).
In this study, antagonistic or delayed bactericidal activity was
observed during the first 24 h when gentamicin was added to
daptomycin. This has been observed in clinical studies (16) and
in vitro studies (34) with vancomycin, but to our knowledge,
this has not yet been observed with daptomycin. We believe
that this effect may be isolate dependent and may be due to the
biofilm.
The biofilm formation by two MRSA isolates obtained from
patients with SAIE was quantified. Both clinical isolates pro-
duced 38 to 49% more biofilm than a characterized non-bio-
film-forming control (strain ATCC 12228) and slightly less
biofilm (5 to 12%) than a characterized biofilm-forming isolate
(strain ATCC 355556). The daptomycin MBECs in a 24-h
mature biofilm of the clinical isolates were 8 to 16 g/ml, which
are 4 to 5 serial dilutions higher than the MIC for planktonic
bacteria; these concentrations are clinically achievable with a
6-mg/kg dose (Cmax, 98 g/ml). For vancomycin, the MBECs
were 64 to 128 g/ml, which is 6 to 8 serial dilutions higher
than the MICs for planktonic bacteria; these concentrations
are not clinically achievable by the use of traditional doses. The
rifampin and gentamicin MBECs were 0.062 and 256 g/ml,
TABLE 3. Change in inoculum from starting inoculum of 5  109 CFU/g at 8, 24, and 72 h obtained with SEV infection model
Antimicrobial(s)
Mean change in bacterial density (log10 CFU/g)
MRSA B341002 MRSA B346846
8 h 24 h 72 h 8 h 24 h 72 h
Growth control 0.42 0.37 1.50c 1.47 1.81 1.51
Daptomycin 3.05a 6.70a 6.70a 1.68 6.61a 6.36a
Daptomycin  gentamicin 2.07a 3.85a,b 6.53a 0.99 1.97a,b 6.61a
Daptomycin  rifampin 3.18a 5.64a 6.83a 0.88 3.95a,b 6.19a
Vancomycin 0.11 0.70 1.40a 0.13 1.11 2.04a
Vancomycin  gentamicin 0.56 1.40 3.17a,b 0.73 1.08 1.58a
Vancomycin  rifampin 0.06 0.73 2.58a 0.22 1.16 1.81a
a P  0.046 versus the results for the growth control.
b P  0.03 versus the results for monotherapy.
c Positive values indicate growth.
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FIG. 1. Activities of antimicrobials tested alone and in combination against MRSA B341002 (a) and B346846 (b). Dapto, daptomycin; Vanco,
vancomycin; Gent, gentamicin; Rif, rifampin.
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respectively. The observed increase in the MBECs relative to
the MICs is consistent with previous reports of antimicrobial
resistance when bacteria transition from the planktonic form to
the biofilm form (9).
Overall, the daptomycin and vancomycin MICs for both
clinical isolates were higher when they were grown in a high
inoculum or in the presence of 4 g/dl of albumin. The genta-
micin and rifampin MICs were minimally affected by the high
inoculum or albumin, consistent with the findings of other
published studies (24, 34). Daptomycin and vancomycin exhib-
ited high to moderate levels of protein binding; thus, albumin
and a high bacterial inoculum (such as in a biofilm or vegeta-
tion) decrease the free drug concentration, which reduces the
AUC/MIC ratio and decreases the antimicrobial activity. In
the presence of a high inoculum and albumin, the increase
in the daptomycin and vancomycin MICs and the preservation
of the rifampin and gentamicin MICs were not correlated with
activity in the in vitro model.
In conclusion, both of the clinical MRSA isolates obtained
from patients with IE quantitatively produced biofilms. The
addition of gentamicin or rifampin to either vancomycin or
daptomycin did not increase their antibacterial activities in a
sequestered high-inoculum model of biofilm-forming MRSA
IE, and rifampin and gentamicin were shown to delay the
bactericidal activity of daptomycin during the first 24 h. Over-
all, daptomycin monotherapy had significantly better activity
against both of the biofilm-forming MRSA isolates than van-
comycin.
A limitation of this study is the use of only two clinical
MRSA isolates. In addition, we cannot conclude that our re-
sults will hold true with treatment durations longer than 72 h.
Our findings on the activities of daptomycin and vancomycin
monotherapies are consistent with those obtained with clinical,
in vitro, and animal models published previously; however,
until now, biofilm formation has not been quantified (16, 25,
33, 34). To our knowledge, this is the first study to evaluate the
activities of these agents against biofilm-forming MRSA in a
sequestered high-inoculum model of IE. The results support
the use of daptomycin monotherapy for the treatment of bio-
film-forming MRSA in a simulated endocarditis vegetation.
Nonetheless, our results should be applied to clinical practice
with caution. Confirmation of these results in clinical studies is
needed before these regimens can be adopted for use for the
care of patients.
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